Cholesterol Management: Targeting a Lower Low-Density Lipoprotein Cholesterol Concentration Increases Adult Treatment Panel-III Goal Attainment

American Journal of Cardiology

Volumn 97, Issue 11, 2006, Pages 1667-1669

  Crouse III, John R ^a   Elam, Marshall B ^b   Robinson, Jennifer G ^c   Ambrosius, Walter T ^a   Ginsberg, Henry N ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ARTICLE; CLINICAL TRIAL; HUMAN; MYOPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 33646703812     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.12.060     Document Type: Note

References (13)

1. NCEP Expert Panel. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Foley K.A., Simpson R.J., Crouse III J.R., Weiss T.W., Markson L.E., and Alexander C.M. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 92 (2003) 79-81
3. Foley K.A., Vasey J., Berra K., Alexander C.M., and Markson L.E. The Hyperlipidemia: Attitudes and Beliefs in Treatment (HABIT) survey for patients: results of a validation study. J Cardiovasc Nurs 20 (2005) 35-42
4. Robinson J.G., Conroy C., and Wickemeyer W.J. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol ≤100 mg/dl. Am J Cardiol 85 (2000) 305-308
5. Davidson M.H., Maki K.C., Pearson T.A., Pasternak R.C., Deedwania P.C., McKenney J.M., Fonarow G.C., Maron D.J., Ansell B.J., Clark L.T., and Ballantyne C.M. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
6. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K., and Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
7. Huser M.A., Evans T.S., and Berger V. Medication adherence trends with statins. Adv Ther 22 (2005) 163-171
8. Brewer B. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 92 suppl (2003) 23K-29K
9. Benner J., Pollack M., Smith T., Bullano M., Willey V., and Williams S. Association between short-term effectiveness and statins and long-term adherence to lipid-lowering therapy. Am J Health-Syst Pharm 62 (2005) 1468-1475
10. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
11. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., and Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
12. Smogorzewski M. The myopathy of statins. J Ren Nutr 15 (2005) 87-93
13. McKenney J.M. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering. benefits versus risks. Am J Cardiol 96 suppl (2005) 60E-66E